Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in <i>RAS/RAF</i> Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy.

导出 OA

翻译打印收藏纠错

第一作者： Christine M,Parseghian

第一单位： Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

作者： Christine M,Parseghian ^[1] ; Ryan,Sun ^[2] ; Melanie,Woods ^[1] ; Stefania,Napolitano ^[3] ; Hey Min,Lee ^[1] ; Jumanah,Alshenaifi ^[1] ; Jason,Willis ^[1] ; Shakayla,Nunez ^[1] ; Kanwal P,Raghav ^[1] ; Van K,Morris ^[1] ; John P,Shen ^[1] ; Madhulika,Eluri ^[1] ; Alexey,Sorokin ^[1] ; Preeti,Kanikarla ^[1] ; Eduardo,Vilar ^[4] ; Marko,Rehn ^[5] ; Agnes,Ang ^[5] ; Teresa,Troiani ^[3] ; Scott,Kopetz ^[1]

作者单位： Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[1] Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[2] Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Campania, Italy. ^[3] Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.;Division of Cancer Prevention and Population Sciences, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[4] Amgen, Thousand Oaks, CA. ^[5]